See more : Atland SAS (ATLD.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Sharps Technology, Inc. (STSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sharps Technology, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Oceana Group Limited (OCE.JO) Income Statement Analysis – Financial Results
- Yoshicon Co.,Ltd. (5280.T) Income Statement Analysis – Financial Results
- Haima Automobile Co.,Ltd (000572.SZ) Income Statement Analysis – Financial Results
- Hyterra Ltd (HYT.AX) Income Statement Analysis – Financial Results
- Highlands Bankshares, Inc. (HBSI) Income Statement Analysis – Financial Results
Sharps Technology, Inc. (STSS)
About Sharps Technology, Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
Gross Profit | -891.25K | -654.57K | -28.70K | -11.04K | -10.59K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 1.61M | 2.28M | 1.69M | 827.01K | 388.02K |
General & Administrative | 8.52M | 6.46M | 2.81M | 1.51M | 1.51M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.66M |
SG&A | 8.52M | 6.46M | 2.81M | 1.51M | 1.66M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.05M |
Cost & Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.06M |
Interest Income | 0.00 | 1.32K | 769.00 | 3.33K | 3.60K |
Interest Expense | 138.12K | 1.32M | 167.52K | 0.00 | 0.00 |
Depreciation & Amortization | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
EBITDA | -8.98M | -2.66M | -4.47M | -2.33M | -2.04M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -10.13M | -8.74M | -4.50M | -2.33M | -2.06M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 255.01K | 4.10M | -166.75K | -6.87K | 3.59K |
Income Before Tax | -9.87M | -4.64M | -4.66M | -2.34M | -2.06M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -30.00K | -5.42M | 166.75K | 6.87K | 3.00 |
Net Income | -9.84M | 779.89K | -4.83M | -2.35M | -2.06M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
EPS Diluted | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
Weighted Avg Shares Out | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
Weighted Avg Shares Out (Dil) | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes
Why Is Sharps Technology (STSS) Stock Up 194% Today?
Head-To-Head Analysis: NeuroMetrix (NASDAQ:NURO) & Sharps Technology (NASDAQ:STSS)
Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems
Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems
Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ: STSS)
Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals
Source: https://incomestatements.info
Category: Stock Reports